<SEC-DOCUMENT>0001628280-24-011646.txt : 20240318
<SEC-HEADER>0001628280-24-011646.hdr.sgml : 20240318
<ACCEPTANCE-DATETIME>20240318160825
ACCESSION NUMBER:		0001628280-24-011646
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240318
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240318
DATE AS OF CHANGE:		20240318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		24759073

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>advm-20240318.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:24cc9e03-b291-4e30-97e3-60dc9a978e61,g:7425a5d3-cea4-40c7-b05f-f07965ad4f21,d:58b1967b1e66442f9d701bac1bb2a030-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20240318</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501756</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20240318.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-18</xbrli:startDate><xbrli:endDate>2024-03-18</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i58b1967b1e66442f9d701bac1bb2a030_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 18, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.586%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.296%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36579</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">20-5258327</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">100 Cardinal Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94063</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">656-9323</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a&#8211;12 under the Exchange Act (17 CFR 240.14a&#8211;12)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d&#8211;2(b) under the Exchange Act (17 CFR 240.14d&#8211;2(b))</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e&#8211;4(c) under the Exchange Act (17 CFR 240.13e&#8211;4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ADVM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i58b1967b1e66442f9d701bac1bb2a030_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On March 18, 2024, Adverum Biotechnologies, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2023, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Adverum Biotechnologies, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="i58b1967b1e66442f9d701bac1bb2a030_10"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_031824pressrele.htm">Press Release dated March 18, 2024, announcing Adverum Biotechnologies, Inc. financial results for the quarter and year ended December 31, 2023, and providing a corporate update.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i58b1967b1e66442f9d701bac1bb2a030_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"/><td style="width:47.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adverum Biotechnologies, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date: March 18, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laurent Fischer, M.D. <br/>President and Chief Executive Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_031824pressrele.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie9fb0c420f3b41688ec14ddcb4afc913_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="logo.jpg" src="logo.jpg" style="height:97px;margin-bottom:5pt;vertical-align:text-bottom;width:306px"></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%">- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD -</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%">- Completed $127.5 million private placement financing with new and existing institutional investors -</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%">- Cash runway expected into late 2025 -</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%">- 1-for-10 reverse stock split to be effective March 21, 2024 -</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">REDWOOD CITY, Calif., March 18, 2024 - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Adverum Biotechnologies, Inc. (Nasdaq&#58; ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8220;We have made tremendous progress during 2023 and in 2024 to date in our development of Ixo-vec as a durable potential gene therapy treatment for the millions of patients suffering from wet AMD,&#8221; stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. &#8220;We were pleased to present at Macula Society preliminary data from our ongoing LUNA Phase 2 trial of Ixo-vec, which demonstrated potentially best-in-class clinical activity at both the 2E11 and 6E10 doses of Ixo-vec, with the data trending similar to, or better than, the data in our first-in-human OPTIC trial.  Importantly, the preliminary data demonstrated that Ixo-vec was generally well tolerated. We look forward to presenting the 26-week interim analysis of our LUNA Phase 2 program in mid-2024.&#8221; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Dr. Fischer continued, &#8220;In the lead-up to the data presentation at Macula Society, Adverum completed a $127.5 million private placement financing with new and existing investors that we expect to meaningfully extend our cash runway into late 2025, well beyond the anticipated presentation of topline 52-week data from our ongoing LUNA Phase 2 trial. In parallel, we are continuing to interact with regulators in the U.S. and E.U. to inform Phase 3 development of Ixo-vec, which we plan to initiate in the first half of 2025.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ixo-Vec Program</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Highlights&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Preliminary Ixo-vec LUNA Trial Data at Macula Society 2024&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">In February 2024, we announced positive preliminary efficacy and safety data from the ongoing LUNA Phase 2 trial of Ixo-vec in patients with wet AMD at the 47th Annual Meeting of the Macula Society in Palm Springs, California. </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">LUNA patients treated with either the 2E11 or 6E10 dose of Ixo-vec experienced potentially best-in-class reduction in annualized anti-vascular endothelial growth factor (VEGF) injections and the percentage of patients receiving no supplemental injections through 26 weeks. </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.78pt">Patients at the 2E11 and 6E10 doses had mean 90% and 94% reductions, respectively, in annualized anti-VEGF injections.</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.78pt">85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">Maintained or improved mean BCVA and mean CST at both dose levels.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">Ixo-vec continued to be generally well tolerated, with cases of intraocular inflammation responsive to local corticosteroids.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">No Ixo-vec related serious adverse events, episcleritis, vasculitis, retinitis, choroiditis, vascular occlusion or hypotony were reported.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Long-Term Ixo-vec OPTIC Trial Data at AAO 2023&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">In November 2023, the company announced 3-year data from the OPTIC extension study of patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting in San Francisco, California.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">Patients in the OPTIC extension trial continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomic improvements and sustained reduction in anti-VEGF treatment burden.</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.78pt">Patients at the 2E11 dose had an 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose receiving zero supplemental injections through three years.</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.78pt">Aflibercept protein levels have been sustained through follow-up, which is up to 4.5 years post-treatment.</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9642;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.78pt">BCVA was maintained and CST was improved through 3 years.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">Ixo-vec was generally well tolerated, with the most common adverse event being dose-dependent inflammation that was responsive to topical corticosteroids.</font></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Corporate Updates&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Approval of 1-for-10 reverse stock split&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">On March 8, the Board of Directors approved a 1-for-10 reverse stock split of the Company&#8217;s common stock. The Company's common stock will begin trading on a reverse stock split-adjusted basis on March 21, 2024. Following the reverse stock split, there will be approximately 20.8 million shares of the company&#8217;s common stock outstanding.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">$127.5 Million Private Placement Financing&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> In February 2024, the Company completed a private placement of 106.25 million shares of common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors at a price of $1.20 per share, representing a premium of approximately 20% to Adverum&#8217;s 30-day volume-weighted average price. The financing was led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and Vivo Capital, as well as two large investment management firms. The financing is expected to extend Adverum&#8217;s cash runway into late 2025.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Appointment of Romuald Corbau, Ph.D. as Chief Scientific Officer&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> In January 2024, the company announced the appointment of Romuald &#8220;Romu&#8221; Corbau, Ph.D. as Chief Scientific Officer. Dr. Corbau brings over 25 years of experience in drug development, including leading Spark Therapeutics&#8217; translational R&#38;D for Luxturna&#174;, a subretinal injection gene therapy product for Leber&#8217;s congenital amaurosis, an inherited vision loss disease that routinely results in blindness.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Anticipated Milestones</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:12.53pt">2024&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Continued FDA and EMA formal and informal regulatory interactions</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:12.53pt">Mid-2024&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">LUNA 26-week interim analysis</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:12.53pt">H1 2025&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> Initiation of Phase 3 trial </font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Financial Results for the Three Months Ended December 31, 2023</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Cash, cash equivalents and short-term investments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $96.5 million as of December 31, 2023, compared to $117.1 million as of September 30, 2023, and $185.6 million as of December 31, 2022. Including proceeds from the February 2024 private placement financing, pro forma cash, cash equivalents and short-term investments was $223.8 million. Adverum expects its cash, cash equivalents and short-term investments to fund operations into late 2025.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $15.3 million for the three months ended December&#160;31, 2023, compared to $22.2 million for the same period in 2022. Research and development expenses decreased due to lower clinical trial related expense, lower material production and bioanalytics, lower stock-based compensation expense, lower license fees, and lower outside research and development services. Stock-based compensation expense included in research and development expenses was $1.0&#160;million for the fourth quarter of 2023.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">General and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $10.9 million for the three months ended December&#160;31, 2023, compared to $11.7 million for the same period in 2022. General and administrative expenses decreased due to lower facilities expense due to fewer premises leased in the current period and higher sublease income and lower depreciation expense. Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:12.53pt">Net Loss</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> was $23.7 million, or $0.23 per basic and diluted share, for the three months ended December 31, 2023, compared to $32.7 million, or $0.33 per basic and diluted share for the same period in 2022. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">About Wet Age-Related Macular Degeneration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Wet AMD, also known as neovascular AMD or nAMD, is a VEGF driven advanced form of AMD affecting approximately 10% of patients living with AMD associated with the build-up of fluid in the macula and the retina. Wet AMD is a leading cause of blindness in people over 65 years of age, with approximately 20 million individuals worldwide living with this condition. New cases of wet AMD are expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases. Additionally, wet AMD is a bilateral disease, and incidence of nAMD in the second eye is up to 42% in the first two to three years. The current standard of care requires frequent life-long repeated bolus injections of anti-VEGF in the eye. IVT gene therapy has the promise to preserve vision and reduce most or all injections for the life of the patient by delivering stable therapeutic levels of anti-VEGF to control macular fluid.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">About Ixo-vec in Wet AMD</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Adverum is developing ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), its clinical-stage gene therapy product candidate, for the treatment of wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require surgery to administer the gene therapy under the retina (sub-retinal approach), Ixo-vec is designed to be administered as a one-time IVT injection in the physician&#8217;s office, deliver long-term efficacy, reduce the burden of frequent anti-vascular endothelial growth factor (VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD. In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration granted Fast Track designation for Ixo-vec for the treatment of wet AMD. Ixo-vec has also received PRIME designation from the European Medicines Agency and the Innovation Passport from the United Kingdom&#8217;s Medicines and Healthcare Products Regulatory Agency for the treatment of wet AMD.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">About Adverum Biotechnologies</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Adverum Biotechnologies (NASDAQ&#58; ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians&#8217; offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;text-decoration:underline">www.adverum.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Forward-looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Statements contained in this press release regarding events or results that may occur in the future are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the potential benefits of Ixo-vec as a one-time IVT injection for the treatment of wet AMD, including its potential to improve vision outcomes, the potential best-in-class clinical activity of Ixo-vec, and anticipated timing of preliminary and interim data from the Phase 2 LUNA trial and initiation of a Phase 3 trial, and statements associated with the Company&#8217;s cash sufficiency and runway, and other statements containing the words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and similar expressions.  Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation&#58; risks associated with market conditions. Additional risks and uncertainties facing Adverum are set forth under the caption &#8220;Risk Factors&#8221; and elsewhere in Adverum&#8217;s Securities and Exchange Commission (SEC) filings and reports, including Adverum&#8217;s most recent Annual Report on Form 10-K filed with the SEC, as updated by any subsequent reports on Form 10-Q.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate, Investor and Media Inquiries</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">E&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;text-decoration:underline">ir&#64;adverum.com </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"></td><td style="width:53.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.154%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Selected Consolidated Balance Sheet Data</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents, and marketable securities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">96,526&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">185,589&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">173,010&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">308,372&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total current liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32,246&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">89,541&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">126,854&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stockholders' equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">83,469&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">181,518&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(1) </font><font style="color:#636363;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:107%">Cash, cash equivalents, and marketable securities exclude approximately $127.8 million in net proceeds from Adverum's February 2024 private placement</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consolidated Statements of Operations</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands except per share data)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Three months ended December 31,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Years ended December 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Unaudited)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">License revenue</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15,278&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">22,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">77,676&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99,277&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10,880&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11,741&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">49,915&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57,858&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total operating expenses</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26,158&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">33,940&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">127,591&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">157,135&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(26,158)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(33,940)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(123,991)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(157,135)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income, net</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,311&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,223&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,748&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss before income taxes</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(24,847)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(32,717)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(118,243)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(154,462)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Income tax benefit (provision)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,133&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(19)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(74)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(23,714)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(32,736)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(117,165)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(154,536)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss per share &#8212; basic and diluted</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.23)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.33)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1.16)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1.56)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted-average common shares outstanding - basic and diluted</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101,213</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99,915</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100,824</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99,251</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1) Derived from Adverum&#8217;s annual audited consolidated financial statements.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>advm-20240318.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:24cc9e03-b291-4e30-97e3-60dc9a978e61,g:7425a5d3-cea4-40c7-b05f-f07965ad4f21-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20240318" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20240318">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20240318_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20240318_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.adverum.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>advm-20240318_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:24cc9e03-b291-4e30-97e3-60dc9a978e61,g:7425a5d3-cea4-40c7-b05f-f07965ad4f21-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_71423b80-4fb4-4a65-8b5f-c85ee6810e40_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e3e7ea33-de97-4d6b-b25f-3e620f5aa442_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_57f18d14-8199-4fcc-a047-d8114d2cbcdb_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5902f249-2e6b-4fb0-811c-132e4b51dc51_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7cb46db2-07e7-4ed7-8c96-fea7f715bce1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4afe4f9a-86df-4016-bbf8-a07884735821_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_db87fa89-1eee-4935-91f7-c3e4073c0771_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_27cb6631-c547-4852-8a87-b53d3fe704f7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b9483f86-e5fe-482b-96a3-5bea5bde066e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_07e0ecb0-0809-4562-92f3-aefa249349e5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ca1b9a21-5e4f-4460-bc11-37c627f045a1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_c46c5df8-494d-4221-9e18-026479708f22_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b83585d5-f92c-47f3-89ca-75ffebfd0782_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5d1085e9-9a5a-42de-afe2-0b23ff1c59e2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_727c184b-758a-4674-b673-2367e8706bfc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d5b3f5b1-46f9-438b-a5d5-285d8acdc2d3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f1306131-5645-44d9-9911-dd6ac68ea426_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_df248f35-55f0-42fa-b366-504cc7d41f13_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1b14fd28-d3ea-4f55-9726-982b36f711b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fee22c06-7297-460c-84c7-671acc153838_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e6d5c231-3fe5-4a9a-95f3-fb4c6a4fafbc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_751c4d2c-d9ad-4756-9d40-fcf5dc298fe3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>advm-20240318_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:24cc9e03-b291-4e30-97e3-60dc9a978e61,g:7425a5d3-cea4-40c7-b05f-f07965ad4f21-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/Cover" xlink:type="simple" xlink:href="advm-20240318.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7952a44f-df2e-4cba-bfdf-4f15cc896da8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_DocumentType_7952a44f-df2e-4cba-bfdf-4f15cc896da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a352425c-31e7-4431-88f0-929d7f44c4b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_DocumentPeriodEndDate_a352425c-31e7-4431-88f0-929d7f44c4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_75cc2de0-592b-49e4-bcef-1ee611c7ed60" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityRegistrantName_75cc2de0-592b-49e4-bcef-1ee611c7ed60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c885769c-43f5-4d46-8e5c-4d2c37d8a0e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c885769c-43f5-4d46-8e5c-4d2c37d8a0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5fb65713-7636-4c11-85fe-40f319e1d9d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityFileNumber_5fb65713-7636-4c11-85fe-40f319e1d9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_323636e3-6234-481c-9466-275ba53bc1a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityTaxIdentificationNumber_323636e3-6234-481c-9466-275ba53bc1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3fe8d1da-69a9-4b5e-a0ef-2aa2202b1786" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityAddressAddressLine1_3fe8d1da-69a9-4b5e-a0ef-2aa2202b1786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cb7d3049-9836-412d-9d1b-9062169f9b83" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityAddressCityOrTown_cb7d3049-9836-412d-9d1b-9062169f9b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b66ede5e-de88-4f4d-9817-5431070455ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityAddressStateOrProvince_b66ede5e-de88-4f4d-9817-5431070455ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fb2ba7d9-6570-41fa-8a75-4fb43a2991c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityAddressPostalZipCode_fb2ba7d9-6570-41fa-8a75-4fb43a2991c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9c8293d3-488e-4389-ba06-0d732e31551f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_CityAreaCode_9c8293d3-488e-4389-ba06-0d732e31551f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f943f7fc-88dd-4fc1-a191-21374213579a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_LocalPhoneNumber_f943f7fc-88dd-4fc1-a191-21374213579a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e8291fb9-26da-4cf7-bfd1-e37e861d91a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_WrittenCommunications_e8291fb9-26da-4cf7-bfd1-e37e861d91a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_55a9ac81-8482-44e5-a8fc-167dc818c4f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_SolicitingMaterial_55a9ac81-8482-44e5-a8fc-167dc818c4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7f9ccdce-c8ab-4d4f-af66-c528f9506cda" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_PreCommencementTenderOffer_7f9ccdce-c8ab-4d4f-af66-c528f9506cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2933c83c-a210-42aa-841e-ecce5776bd7a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2933c83c-a210-42aa-841e-ecce5776bd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_201fa3bf-62cc-4b08-b3ba-6166fb839603" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_Security12bTitle_201fa3bf-62cc-4b08-b3ba-6166fb839603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e352d95c-5b70-41e1-b84f-9ad1e6bd536c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_TradingSymbol_e352d95c-5b70-41e1-b84f-9ad1e6bd536c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_519052e3-a07d-4c80-a1bf-d7e65d4edf6a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityCentralIndexKey_519052e3-a07d-4c80-a1bf-d7e65d4edf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1bd5d0a4-63aa-477a-9ca3-ac0fd5436ba9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_EntityEmergingGrowthCompany_1bd5d0a4-63aa-477a-9ca3-ac0fd5436ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_04252d33-fd3f-4556-a13f-ffccbe13a98b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_AmendmentFlag_04252d33-fd3f-4556-a13f-ffccbe13a98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_538772e9-2c4d-44c5-8b4b-55d76db5e323" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ecf4b9a0-c332-4a54-9c23-9b510e773db8" xlink:to="loc_dei_SecurityExchangeName_538772e9-2c4d-44c5-8b4b-55d76db5e323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "? ?$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **3-+0 4444 %%%)F@!:*3-&: %HHHH ***3- "T4E+0 4444 %%%)0 M%)
MFEH **3-+0 4444 %%)FC(H 6BDI: "BBDR* %HHHH **2EH ***2@!:***
M"BBDH 6BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"DI:2@!M<+\5/BYHGPCT:*_U<R2&9_+B@A&7<_2NXD8*I). !DU^?/[3'CRX
M^)WQ2DT_3O,NK33R;6VBB^;>X^\P]3GC\*WI4_:/78\#.,Q>7X?FA\3V/N7P
M%XZTSXC>&[;6])D9[6;^%AAD(ZJ:Z3-?$_[&/Q(;0?$UWX1OI/+M[TF2W5OX
M91]Y?QK[7&:FI#D=C?*L<LPPRJOXNOJ/I*6D[5D>P075Q'9V\DTSB.*-2[,W
M0 <DFO"[K]LSX?VMU+"'OYO+<KYD=O\ *V.XYKW*^M(M0LYK:==\,R&-U/=2
M,$5\WW7[#OA*XNY7@UG4H8V<LL*LA"#T'%7"5).U1GBYB\P2C]22?>YM?\-J
M> /34?\ P''^-26_[9WP^F<*SW\0/\36_'X\US__  PIX8_Z#NJ?^.?X56OO
MV$=":$_9/$6H1RXX,JHR_P JZ?W)X7M,_6O+$]H\(_&SP9XV=$TO7;:2=ND,
MC;'^F#UKNE(9<@YKX!^(7[)OC+P#&^HZ8RZW:0_,9+0%)D'7.WO^%:GP/_:J
MU?P7?0:/XJFEU'12WE^?+DS6W./J0/0\BE*BFKP9I0SVI1J*CF%/D;Z]#[JK
MRCXG?M&^%OA9X@MM&U/[1/>RJ'D$"9$*GH6^M>FZ?J%OJME!=VDR3VTZ"2.2
M,Y5E(R#7R)^W#\/FAU#2_&%M&3'*!971 Z$?<8_J/PK*G%2E:1[&;8JMAL(Z
M^'U:_(^M]'U:UUW3+;4+&59[2YC$L<B]&4\@U>7.:^<?V+?B%_;W@BX\.7,F
MZZTE_P!WD\F%NGY'-?1XYJ)QY)-'9@<4L9AXUEU'4AI::U0=YRGQ&^(VD?"_
MPW+K6LR,ENK!$CC&7D8]% ]:S_A1\7=$^+^CSW^CF5#;OY<T$PPZ,1D?F.]?
M*_[:GQ"_MSQE:>'()<VFDIYDP!X\YO\  5[A^R+\/6\%_"^&^N4:._UE_M<B
MMU"8P@_+^==+IJ--29\M1S.KB<SEAJ6L([^IZMXR\8:7X#\/W6LZO/\ 9[&W
M7+-C))/0 >IKQX?MI> ..-2_\!Q_C5G]LK_DBE[_ -?,/_H5?-O[-_P-TKXS
M2:TFI7MU9_8@A3[,1SNSUR*J%.#AS2.7,\QQM/&QPF#2NUU/HG_AM+P!Z:E_
MX#C_ .*H_P"&U/  [:E_X#C_ .*K%_X86\*_]!O5/S3_  I?^&%?"O\ T&]4
M_-/\*?[DGGS_ /EB;/\ PVI\/^F-2_\  <?_ !5=[\+_ (W>&OBVUVFARS>?
M:X,D,Z;'VGHP]J\H_P"&%?"N?^0UJGYI_A7I'P?^ 6@_!J2^GTR>YN[J[ 22
M>Y()"C^$ =JSDJ5O=W.W!RSAUE]94>7K8]-Z<"O)O'W[3/@WX=>()=&U">XF
MOH5!E2VCWA,] 3GK7K5?FU^T%'YWQU\41DX#7RKGV*J*5&"F]33/<PK9?1C.
M@E=NQ]4K^VGX ]-1_P# <?XT?\-I^ /34O\ P''^-<UIO[#_ (9OM/M;@ZYJ
M:F:)9"!LZD ^E6?^&%?#'_0>U/\ \<_PK6U'N>7&IG\E=1B=/I_[8WP\OIQ&
M]S=VF3C?/!A1^1->J^%_&VA>,[,7&B:G;ZA%W\EP2/J.H_*OFKQ!^PE:_9V;
M1O$=PLX'"7<:LI/U&,5X#J6F^,_V>?&L:F233=0B.^.2-B8;A,_J#Z&CV=.?
MPO4SEFV99>T\=2]U]4?IC5>^O(M/LYKJ=Q'!"AD=CV4#)-<5\&?B9;_%;P+9
MZU$HBN/]5<PY^Y*/O#Z=ZV?B,=O@'Q!_UXS?^@&N7EM+E9]BL1&I0]O3=U:Z
M.)^''[27A7XF^*)]#TQKB.Z4,T33( LRKU*UZTO2OSM_9%_Y+7HO_7"7_P!
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M\;8S@CZ5\1_M2?$;_A/OB==0P2[]-TH&T@QT+ _.P^IX_ 5[5^P?QX7\3?\
M7['_ .@&NMT5&GS'QF&SN>)S1X6-N17_  /J44ZFX/>G5R'V@M%%% !1110
M4444 %%%% !1110 4444 %(W2BD9AB@#RW]HKXD+\-_AM?W43A=0NE^S6JYP
M=[<9'T'-?.G[&OPU;Q)XIO/%6H1F2VL<I"SCAYFZG\ :Q/VJ/'D_Q(^*<7A[
M3"T]KITGV2)$Y#W#'#'\#Q^!K["^$'@&'X;^ =+T:-1YT<8>=A_%(1EC^?\
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MIJM.A3;W9V?[(/Q";P;\1)= O6,-IJF8=K'A)U/']17WAVK\]?VDO!4_PO\
MBX^I6"M!;7KB_M77@+)G+ ?CS^-?;/PF\<0_$/P'I6MQ,&>:("8?W9!PP^N?
MYU-:*=IHZ.'ZTJ,JF7U=X/3T.RZUYM\?_B(GPW^&NJ:@CA;V9?L]JN>3(PQG
M\!S^%>D# 6OA3]LCXBMXI\=Q>'K1]]II(VLJG(>9L9_+@5E2AS2/8SK&?4\)
M*4?B>B^9X='H=Y?:'?:XP)M8+A('D;JTCY.!^ .:^M_V#L_\(SXF_P"OR/\
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MQ9N;/<?X3]]?P//XU]:"N*K>,K,^[RBM2Q&$A.G&W1^IB>.O^1,US_KRF_\
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M'B:68T^CLS]$[JYCL[>6>5@D<:EV)Z  9S7YO^/M6O?CA\:IEM"TGV^[%I;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139981018718336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 18, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 18,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  ,@7)8JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    (  R!<EAED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ,@7)8)!Z;HJT   #X 0
M&@              @ &?$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  ,@7)899!YDAD!  #/ P  $P              @ &$$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #.$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="advm-20240318.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="advm-20240318.htm">advm-20240318.htm</File>
    <File>advm-20240318.xsd</File>
    <File>advm-20240318_lab.xml</File>
    <File>advm-20240318_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "advm-20240318.htm": {
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20240318",
   "dts": {
    "inline": {
     "local": [
      "advm-20240318.htm"
     ]
    },
    "schema": {
     "local": [
      "advm-20240318.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20240318_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20240318_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.adverum.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20240318.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20240318.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-011646-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-011646-xbrl.zip
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MDB$?GFY.-[(-2B"##(J5\V$=ALK+S]VZ[AJKAPS=5,_+"IXH!G.ZV(DLJ7<
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MSO1S5XZD+,@X1[XYT9J5*6QMQLH=Y\W+R?=HON)QN)D=XWH3ZDU/!D*H$*C
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MY86Z;;F"_KL>NI:S#U6KKULW_P]02P,$%     @ #(%R6!\$'EUJ @  ;0<
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M3##<YS@G*?)$A)0*P<9/*87@@7)GC1]$Q!-S_1@8<=7Q[>*-)#!\?QN6KEQ
M][B7Y$9K!I:P('!7$T$2XX4G4D:MHI? V6Z"P\=6^S$PXO+C8"EWAL*[V3,-
M+[#AY.#A0OO2/@Q_<O _4$L#!!0    (  R!<ECI/=O[31X  #47 0 >
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M0N@IS).K!.A 2;\2-7>'QH^J, A)"@ ><7D,J7-?IZQ HH#VL)@8R\0#;((
M@$_:]M/_CM$CT/_T1@I15+X&$*P\+\@2"FK%;'0%YJ:*KG1@.L]_W ZG561A
MK<C">W #:U]$'!;(UL'NV<#"\?$GRIO</M!3L=ARQ_XCZ.^P+W2V3J<3BFQ=
MX>$W:I30F_7?-9XHM$S\DZ29?S5CU<WXZR;[A7=^1J8$QSSKHV4'> ;O_)1?
M%?4A(1S1 Q/BV..^"&G-3^-1.@+O'9-(5^P Z.&E3J3-N?Y@SI_#G6]C#)PG
MGIKQ\BO"N2O"*1PQ$SB?IP4=QLD5,&K+J4\/BA/62Y'E^Z"1!S+5-)7S?VZ]
M-RB+3!IYH() 36K9&/TUD->43PO1%!68(2$W_5+BDRV=(I4!)NW@6QYQ, ^E
MEYNJH78W,":5)<:0G0LDY![@-)G:SV+ ?.4'WK,C3UX"NN_ P-VRT[Z&DVYL
MN%;C11[]&_-89Z^6/F8:R_D/&&XW>I+P5PA-CQ49W!T9' ]@90RVC5-,%J<"
M$*W=1%U*T1<B*C%JCHV2.- I/9DPG8]MVBTC-< =3&L%"U=(NSNDD9N/=03A
M-!9 Q:W@\./715!@3I!7ZO?./=SKJCE*=2@A\ ):=2'6)I1=)V P%($H$6N^
M& N"\*S/JRL+>#+G_ *NY%KN[W5I\B7X[VV]:'"A)KM*)M^SRW<\1@&ATWS7
M5:'J<LA=Y(X_1:9JM*L]HC^5J:$\E6 X4"D*'QLIQZ^OI#76R(GVJ1 Y3N<H
MR;F1KM0UDN:*WV9_ R:FFIPA&MHQ)\,7N7C9LVK<_PMT)>RISZDD*YJKV[79
M6]*<N1^V9 TZ;RSRQ^IC_I @#$2 R5^[6]0K)2,>ZX!9R6E<>D"FLI0J4>'!
M53#E'CG+5)1],!@Z,Q5E9T5%V=N\HFQW91F+Q00E_IBICULLB$.!46^#$EQ"
MA#,$=Z!BK$:H#;((*XTG/(ZY<5<#*3)-Y&KP$E499XD(L&IN".;*6 > RTT/
MU%?B>>"-2-S72/ @'5$QM8E>R"0ME>*!NJ2M:Z_TN6.[=4PHZYUB0+)444EU
M@Z',0G)5YUCM!6[.U T6;-6HU[ T^U(%62@,I!%8<!6FJ^FY6IZ4B@=!>P<H
M%:[8EY.__:^V"PKWB+0\.>#7U!=.O>[6\0?V#;:?Q9B;.T&@^PI@<<+'2+L6
MAE[^(^&\[^5 L'./7'ZX\KT:JF1ZU3D/$QYS+ XNOH-E8T3>WZ<0-K^Q,]@M
MF#G:<_\F+]5T)3@<&3[P-YU@.6,\%&;G1#,ACP RIIXR#I-YZ("@+#H^*$Y!
MI9+S<%]=-ED)M/LU%12 .V?^SRK,>$!]='V>6>QL9)_:B/D3*D,G:DOE0'KL
MDZY#WZF8^Q\>S4FYQ<@JE=DN/Z0I.L:/>1'JVN>V&58RZ\M9G^J=&%@K,7-;
MTZA:*20'<M&/LV&Y<K8<:L.*9_Q[#E+C ODGYF,!\M%+#(.@;1(E 3<B\_.O
MOS2Z1Z?4A? ^^P'"(N*__N)TFD?8UY)D?4K+E$,MLWT,( @Q]*/O%WW$8V%6
M1' ER00>\BQ6"69S.(:(1IC_ 9#J0" +%+9<Z)86[<6 >(>GHG#-VUC@V'W
MG1^)!.3"9C6^5=IZ>=IZRZV\I1)U,'M07477M-7NEPSNW+L,7@F[SBJ)6]3L
M;MWQZI SGJ?LWY[J6I(W'XY1#(3&$-.5_M2)9KH"KHIV 8S85IB_->8_F!:=
MW6&?2D=7=1A5F+TU9O_ND*6Z$V.HHXTAZK,QK4-YFXY.$OY,Q'!EQ_668XB+
MXR#R_LLOE#CZ "N,$O:&G-%3X>F,>T.'91JW[RO?*])WW)V1/CQZ!>EC8[^E
MO3?Q[TSJAF>3 !ZI.-5YZ*F[F&R9/PAHNMSH>:]=Z@;D9*(OT(JE?8A8.ZO/
M':=C.W/WG(MQ:FZJYS?A>9\[W9;=ON$!+O;GY68_F.&>$'XRK?F8B=Q<U[&(
M?<)**VZ"_D8XH(C%<]=M3*.-=M%!J9UUL-W3Y!8K ] P)L34&+,DE./=T)VO
MN/'VW C245!$&C%4[M)$I$:)V"7W.2V[43!'+KYUWC_4XEO,B&_P9]OUHQ5\
M"7SD+BR6\)!Z2Z3*>_^!VVX$"7R)X[:P0][/3.'I!-N3\QYUK4;S$DESFV6N
MPF@B_6Y<:N)\>%)?*C*LT(?/KZ70::U/C\+3P#I:9\^M&4@//[*!$(D6+?I[
MC/)+'],**XX$"+J$>\'5/K_A42;V0$-85J]7@(CDA6/7-4[FX3XWI$)W]C8J
M1K]'1O^;3DKKV+D? J72- ),'N\#J]?MWIVQNN/8G?58?0V@K&+V ?>PI V'
ME.4<8GX?"/R=T@AXOYFE8<KRO"RF$1YF)_A@'+*"O)[UZ5)D-!6*$A?[F*#P
MY P[;LBPPS4.2BS;*!DOM^76O6+&O73_/HJ4O5?)MCE.NW[:E&M,>82&GSRO
MVVZ#TF*8JO:T9)<8_O3S1-D:?+G**FZXBX]K7/NXZQGW9]W0M:M?MN^Y'O=!
M:[/O6*,]%+7/QHC0G=,Q %JS,G+Z/O?P;SEO]MT,3-+SK"XB-2%W*A*J:"O!
MBG<@J8@NDSBZB0I6??"8!!5A<4K_T-@2G)6$#>UZVAJFA6<RP4Y]ME<RT'6K
ME,6E^Y)$H;S.NZR1C/N9#&A&#19/!YDL-$*H>^+S3F>=A[&9.9'>:9[M\;B9
M+5;D2*@;7ZAQ('0VJ5W*)O&A,"5G\XGL0L3#*K!W/P.PL8F* W^"YF+Y/.E(
M4H['IYR(S3Z*R;0OJ^C\C\5,RA;;NEDBAQ%FP&@L4FEUCJ6@XRPPSA[LTLY/
M6EY#@OCP4N9VI_4MYJ#3I?IXF&;=FIM#X'DJT^E\%")+<9>.L.:8#H*.K#X=
MUNQ9Q3($^;Y$_D/5:1)7E@EZ>SAQ2U<41'2UQF8B$%9,7(E2":S[8G:<#6;%
M:531M(19#V4SQL'"C+@8?6FLJAC@O_"20 Y$#<OVL7Q!-_3W59 EY5)I*K:?
M%F;3!F!C-GOW[<ML=F^$J7H:6Z70:"FF3,5@'YCD'9Z:RK]-\2("-IBIS,X%
M-FYM6O)-+(*(\@60E9YQ!N?#D6GI-&N9UQC/;!EV@?T*L0H,D\2:<];-[Z\E
MZZMDX3H]KCO1@:6!(T8:[J?RR>-@,LE]8:IB^:' (%+$9XF*%1A#EPJ/<U!,
MOT)=(V+*?@]$;&PE8$6<-UD#.^>EI6-JLU,GE^;E/:SEPV+9DIE6=,M,);5=
M !6X#GLW$JIX4N-8BA2CB)=43 G+C1/I6^SX^)O=";L8T8OC*]*$( I*/0*>
MTI/T2"R!;,#JKMA45FC619:>>00(>1R^B$(%Y&^"0_=L]C4*Y 6(#1I'HDQK
M&<B%TF'1U=)5 UH:@L<4#P4LB$ S/HUY]@R(IEO2NI4=@*M5R^L=2#MP;P2P
M+N@-\8C:J^A3GBZ/E5T(,P5$D$JP3%&63FLFC)0=CZ[ J)4\*JHD]!1&*Y>"
MI8ZK?"R/E8M7;2U@?Q/9"KG$O_40%;"WQ[!50'8ACJFF3U*?%FDSW1^0BWK@
M/?1 M41?VCI((^/ )U7#2!;CYV#;D= 6%!6NE>AO/-40^6C+Z=BXM\HXPJ=8
M[W)<\DZQ" 6K!#'YS$'G?(FY=V%P8ZKD8,4<;>O1/:HZ,A*+L15GG]]]>#.[
M:AY<?Y,!W>+HA _"!WR"P85&>61F*.$5[Z((3$RZZPR(F09D%[=_C:C\Y1_
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M_P=02P$"% ,4    "  ,@7)8.&?8>P,/  #L70  $0              @ $
M    861V;2TR,#(T,#,Q."YH=&U02P$"% ,4    "  ,@7)8'P0>76H"  !M
M!P  $0              @ $R#P  861V;2TR,#(T,#,Q."YX<V102P$"% ,4
M    "  ,@7)8-Y60Q0(*  !]5   %0              @ '+$0  861V;2TR
M,#(T,#,Q.%]L86(N>&UL4$L! A0#%     @ #(%R6&=HK]FJ!@  W#   !4
M             ( ! !P  &%D=FTM,C R-# S,3A?<')E+GAM;%!+ 0(4 Q0
M   (  R!<ECI/=O[31X  #47 0 >              "  =TB  !E>&AI8FET
M.3DQ7S S,3@R-'!R97-S<F5L92YH=&U02P4&      4 !0!0 0  9D$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>advm-20240318_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20240318.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501756</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-03-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36579</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">656-9323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
